Daytrader Biontech WKN: A2PSR2 ISIN: US09075V1026 Kürzel: BNTX Forum: Aktien User: Stay_Bullish

2/2 2     Von der Leyen, who last month announced a plan to invest €1bn in vaccine production in Africa, said she believed the African Union’s goal of producing 60% of the continent’s vaccine consumption within the continent by 2040 was both do-able and realistic. The EU plans to invest in strengthening the regulatory framework in Africa, helping boost local skills and universities, and building on an existing clinical trial network targeted at infectious diseases.   “We need to join forces here,” she said, adding that the EU was in discussions with countries including Senegal, South Africa, Rwanda and Ghana. Support from institutions such as the European Investment Bank would help incentivise investment as the EU took on some of the risk, she added.   At the G7 summit where leaders will discuss ways of broadening the availability of COVID-19 vaccines, Von der Leyen is likely to call on more countries to increase their exports to other parts of the world. By the end of the week the EU will have produced 700m doses of COVID-19 vaccines, of which around 350m have been exported, she said.   “We would be really happy if other vaccine producers would follow our example, because then it would be a completely different situation where fair distribution of vaccines is concerned.”   Quelle (Biontech): https://biontechse.gcs-web.com/node/10211/html#bntx-ex991_7.htm Ging auch per Mal raus.

1/2 Financial Times, 10.06.2021 BioNTech prepares expansion into Africa alongside EU   By Erika Solomon in Berlin and Sam Fleming in Brussels   BioNTech is planning a push into Africa, aiming to establish mRNA vaccine production facilities on the continent as part of a long-term effort to tackle diseases beyond COVID-19.   The German biotech’s plans come as the EU moves to bolster vaccine manufacturing capacity in Africa, which imports more than 99% of the jabs it uses.   BioNTech co-founder and chief executive Ugur Sahin outlined the effort on a joint video call with Ursula von der Leyen, European Commission president, ahead of the G7 summit in Cornwall.   “From the technology side, there is no reason why [vaccine production in Africa] should not be possible,” Sahin told the Financial Times. “And because there’s no reason any more, we have to make it possible.”   Von der Leyen said the EU wanted to help foster a “strong initiative to invest in mRNA, together with our African partners”, adding that it was important that the technology is brought to the continent. “We are joining forces in a way that everyone brings in the best competences they have.”   Africa, and many of the diseases that afflict populations, such as malaria, has long been neglected by the pharmaceutical industry in favour of research into more profitable medications.   Now wealthy nations and companies are under intense pressure to boost the availability of COVID-19 vaccines on the continent. Only 39m jabs have been administered in Africa so far — just over 2% of global vaccinations.     Last month the EU and the drugs industry were wrong-footed when the Biden administration called for an outright patent waiver to expand global vaccine access to the shots and save lives. Brussels has countered that the focus should rather be on the removal of export restrictions, the expansion of production, and the use of existing intellectual property rules to allow necessary patent licensing.   Washington will also announce new commitments to lower-income countries ahead of the G7 summit, with plans to purchase 500m doses of the BioNTech/Pfizer jabs at cost and donating them to the COVAX scheme, backed by the World Health Organization.   But developing vaccine manufacturing in Africa will take time. Sahin said he aimed for BioNTech to have found and trained a partner in Africa to “fill and finish” vaccine doses in around 12 months, which would enable the continent to import vaccines in bulk.   Establishing capacity for the earlier, more technical stages of manufacturing, when mRNA is produced and then combined with lipid nanoparticles, would likely take about four years, he said.   Advocates of mRNA argue that the new technology, which only had its first big breakthrough with the development of coronavirus vaccines, could be an extremely useful tool to fight disease in developing countries. Facilities producing mRNA can be adjusted within weeks to make different vaccines, and can usually produce larger amounts in much smaller facilities.   BioNTech has revised production targets for its COVID-19 vaccine, developed with US pharmaceutical company Pfizer, up to 3bn from 2.5bn for 2021, but the majority will be sent to higher and middle-income countries. About 1bn of those doses are expected to be sold at-cost for lower-income nations.   An mRNA vaccine for tuberculosis, which the German biotech is developing with support from the Gates Foundation, is likely to be one of the first potential candidates for African production. BioNTech is currently aiming to start clinical trials for the treatment within a year, Sahin said. “HIV is a difficult beast,” he added. “So that comes last for vaccine development.”   All of BioNTech’s future facilities in Africa would produce treatments at non-profit rates, for middle and low-income countries, Sahin said.  

Muss es etwas wirr posten weil der Beitrag 4000 Zeichen nicht überschreiten darf😂

Und jetzt die Bombe, die man halt beim Überfliegen übersieht und wie ich sie einschätze!⚠️ Von der Leyen (EU) will ja eine Milliarde (Siehe FT Artikel) in die Impfstoffproduktion in Afrika investieren. Ich denke, das Geld endet fast komplett bei Biontech! Dort wird eine günstige Produktionsstätte aufgebaut (von der man auch schneller auf andere Kontinente Kontinenten liefern kann), bezahlt von der EU und dort werden auch auch die Dosen "500 Mio" Dosen der USA kostengünstig produziert und wahrscheinlich gleich im Land verteilt. CoVax umgangen, für Curevac wirds immer enger. Konkurrent weiter geschwächt und mindestens 0 auf 0 Deal (sprich Produktionsstätte "geschenkt" dank der EU). Ja, die 500 Mio. werden ohne Gewinn verkauft, aber (wenn das so läuft!), dann macht man dennoch Gewinn weil man ja keine Kosten hatte. Ich bin bestimmt nicht schlauer als die, daher werden die da auch drauf gekommen sein. Das wird sich die nächsten Wochen zeigen.

Jetzt ist es interessant wie der Ami solch eine Nachricht aufnimmt (non Profit und so)? 🤔

Wird kein Geld verdient! (Zumindest angeblich.). Jetzt kam noch eine Mail - dafür folgt dies -> "On June 10, 2021, BioNTech SE (the “Company”) was the subject of a Financial Times publication in which the Company announced that it is aiming to establish mRNA vaccine production facilities on the continent as part of a long-term effort to tackle diseases beyond COVID-19. The publications are attached hereto as Exhibit 99.1." Deutsch: "Am 10. Juni 2021 war die BioNTech SE (das „Unternehmen“) Gegenstand einer Veröffentlichung in der Financial Times, in der das Unternehmen bekannt gab, dass es als Teil einer langfristigen Maßnahme zur Bekämpfung von die Errichtung von Produktionsanlagen für mRNA-Impfstoffe auf dem Kontinent anstrebt Krankheiten jenseits von COVID-19. Die Veröffentlichungen sind diesem als Anlage 99.1 beigefügt." Quelle (BioNtech) https://biontechse.gcs-web.com/node/10211/html#bntx-ex991_7.htm

Die geben die für Umme raus? 😁🙈

Heißt?

Ähm ich Vogel, da steht ja "not for profit price". 😳🙈

Bin jetzt echt gespannt. 🙂🤞

😁😅

Die haben in Sachen Pressearbeit aka Kurs pushen einiges dazugelernt im letzen Jahr!😅👍

Wurde gerade veröffentlich😅 (vor 6min per Email hihi) ...das haben die Amis zum Frühstück im Postfach: "On June 10, 2021, BioNTech SE (the “Company”) and Pfizer Inc. today announced plans to provide the U.S. government at a not-for-profit price 500 million doses of the companies’ COVID-19 vaccine, 200 million doses in 2021 and 300 million doses in the first half of 2022, to further support the multilateral efforts to address the surge of infection in many parts of the world and to help end the pandemic. The press release is attached hereto as Exhibit 99.1." Quelle (BioNtech): https://biontechse.gcs-web.com/node/10206/html

"Ich vertraue nur meinen eigenen Prognosen, deshalb kann ich den Tag noch vor dem Abend loben". Ist natürlich nur mein aktueller (!) Tradingansatz. Das kann auch anders laufen, Bullenfallen und erneute Konsoldierung bis/unter 190€. Deswege sitze ich ja dann immer vorm Schirm. 😊 Aktuell wollte ich mal wieder ins Risiko gehen und meine Prognose vorher (15:30) posten.

Im Hauptforum wird laut Quelle US-Foren von fallendem Kurs für heute vorausgesagt!?

Da ich das Risiko ja nie scheue, neuer Fahrplan: Wenn wir grün sind bis die USA aufsteht, sollten wir heute schon über 200€ schließen. Rechne in der nächsten Woche mit dem erstmaligen Knacken der 220€ Marke. Sollte dann (weil auch der Newsflow passt) unser Schätzchen bis 250€ durchlaufen, würde es mich nicht wundern. Ob ich solange halten würde weiß ich nicht, aber spätestens bei/nach der Konsoldierung wäre ich wieder dabei.